Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02968836
Other study ID # 15.04.CLI
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 1, 2017
Est. completion date December 31, 2019

Study information

Verified date April 2022
Source Nestlé
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Assessment of the Safety and efficacy of an amino acid blend on muscle and gut functionality in Intensive Care Unit (ICU) patients. Since this was a proof of concept, exploratory trial, we assessed different primary outcomes without hierarchy.


Description:

This monocentric trial was a parallel, randomized, double-blind, controlled study. Patients hospitalized in the ICU for sepsis or ARDS were enrolled. The treatment group (n=15) was administered the study product (amino acid blend) and the negative control group (=15) was administrated maltodextrin only. The mode of administration was nasogastric probe. The treatment period was 21 days. Subject were followed during stay in High care and intermediate care units up to 2 months or after hospital discharge with a follow up until 12 months. Recruitment stopped when 30 patients (15 in each group) reached V4.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date December 31, 2019
Est. primary completion date September 30, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients aged 18 and over 2. Sepsis or ARDS patients: expected to stay at least 21 days in ICU (or midcare), to the opinion of the investigator 3. Informed consent signed by the patient or/and by his/her representative Exclusion Criteria: 1. Patient with muscle mass loss due to previous hospitalization 2. Intolerance to enteral feeding 3. Patients using parenteral feeding 4. Chronic renal failure to the opinion of the investigator 5. Chronic liver disease to the opinion of the investigator 6. Cachectic patients 7. Current treatment with paralyzing drugs 8. No pacemaker or metal implants interacting with MRI and magnetic stimulation 9. Pregnant woman (known) 10. Persons without social security 11. Under guardianship 12. Currently participating or having participated in another clinical trial within 4 weeks prior to trial start 13. Patient who is expected not to comply with the study procedures, to the opinion of the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Blend of amino acids
The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
Maltodextrin only
The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.

Locations

Country Name City State
France Hôpital Raymond Poincaré (AP-HP) Garches

Sponsors (1)

Lead Sponsor Collaborator
Nestlé

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety: Renal function change Renal function will be daily assessed from urine output, serum creatinin and glomerular filtration rate 60 days from the beginning of the intervention
Primary Efficacy: muscle functionality change i. Muscle (quadriceps) extension isometric strength in response to magnetic stimulation; diaphragm muscle strength in response to magnetic stimulation. Forced vital capacity and maximal inspiratory and expiratory pressures will systematically be recorded.
ii. Loss in quadriceps muscle mass and metabolism will be measured by Magnetic resonance imaging.
Muscle protein catabolism will be evaluated from measures of 3-methyl histidine in the 24-h urine (reported to urine creatinine).
12 months from the beginning of the intervention (timepoints: D1, D7, D14, D21, D60, D180, D365)
Primary Efficacy: gut barrier structure and functionality improvement i. Enterocytes damage by measurement of I-FABP (intestinal fatty acid-binding protein) in plasma and urine.
ii. Functional enterocyte mass by citrulline plasma concentration. iii. Gut barrier function by the translocation of bacteria based on plasma D-Lactate concentration
12 months from the beginning of the intervention (timepoints: D1, D7, D14, D21, D60, D180, D365)
Primary Efficacy: inflammatory status change i. Calprotectin in feces, which is secreted by the neutrophils of the gut mucosae and is released in the gut when the mucosa is inflamed.
ii. Acute phase protein concentration in plasma (CRP, fibrinogen, ferritin, prealbumin)
12 months from the beginning of the intervention (timepoints: D1, D7, D14, D21, D60, D180, D365)
Primary Efficacy: general recovery improvement i. Length of stay (LOS) in High care and intermediate care units. ii. Time (days) free of ventilation until discharge high care. iii. Time (days) to recover on walking with or without aid 12 months from the beginning of the intervention (timepoints: D1, D7, D14, D21, D60, D180, D365)
Primary Nutrient profiling Nutrient profiling will be assessed from blood metabolomics analyses Over 60 days from the beginning of intervention (timepoints: D1, D7, D14, D21, D60)
See also
  Status Clinical Trial Phase
Completed NCT02913677 - Prolonged Minimal Enteral Nutrition Versus Slowly Advancing Enteral Nutrition in Very Low Birth Weight Infants: N/A
Not yet recruiting NCT00916591 - Prokinetic Drugs and Enteral Nutrition N/A
Completed NCT01025167 - The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and Chemotherapy in Cancer Patients N/A
Not yet recruiting NCT05900323 - Enteral Nutrition Guidelines and Patients' Outcomes N/A
Completed NCT03153397 - Effect of Prebiotic Fiber- Enriched (scFOS) Enteral Feeding on the Microbiome in Neurological Injury Trauma Patients (PreFEED Microbiome Trial) N/A
Completed NCT02353689 - The Effect of FODMAP Content in Tube Feeding Formula on Feeding Intolerance and Nutritional Status Improvement Phase 2/Phase 3
Terminated NCT00564655 - Regional Anesthesia Block of the Transversus Abdominis Plane in Children Undergoing Gastric Tube Insertion Phase 3
Completed NCT06134674 - Early Versus Delayed Enteral Nutrition in Critically Ill Adults With COVID-19
Recruiting NCT03791866 - The Th9/IL-9 and Early Enteral Nutrition in Sepsis N/A
Enrolling by invitation NCT06161350 - The Multi-disciplinary Approach of Children With Feeding Difficulties and Tube Feeding in UZB Between 2000 and 2021
Active, not recruiting NCT02724631 - TubeClear® Evaluation in Pediatric Patients (Phase I) N/A
Completed NCT01988792 - Human Milk Fortification in Very Low Birth Neonates N/A
Completed NCT00600678 - Gastric Emptying Study After Administration of a High Caloric Sip Feed N/A
Completed NCT02998931 - Trial of Enteral Glutamine on Clinical Outcomes in Critically Ill Patients Phase 3
Not yet recruiting NCT06411873 - The Effect of High Protein Enteral Nutrition on Critically Ill Postoperative Children N/A
Recruiting NCT03176875 - Comparison of Partial and Exclusive Enteral Nutrition in the Treatment of Active Childhood-onset Crohn's Disease N/A
Completed NCT02779335 - Enteral Formula Tolerance in Pediatric Patients N/A
Completed NCT05411848 - 2kcal Tube Feed Study N/A
Completed NCT04868318 - The Impact of Intervention With High-protein Enteral Formula in SICU. N/A
Withdrawn NCT04601571 - Confirming Feeding Tube Position Using CORTRAK N/A